Autonomix Medical shares are trading higher after the company reported preliminary results from its clinical trial of RF Ablation technology where 100% of its responder group was able to eliminate opioid use and reduce pain scores.
Portfolio Pulse from Benzinga Newsdesk
Autonomix Medical shares rose following positive preliminary results from a clinical trial of its RF Ablation technology, showing 100% of the responder group eliminated opioid use and reduced pain scores.
October 28, 2024 | 12:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Autonomix Medical's stock is trading higher due to successful preliminary clinical trial results for its RF Ablation technology, which showed significant benefits in pain management and opioid use reduction.
The clinical trial results are highly positive, showing that the RF Ablation technology is effective in eliminating opioid use and reducing pain scores. This breakthrough is likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100